Promomed Group started supplies of Enoparin® to medical institutions
The first batch of Enoparin® anticoagulant, for which the company received marketing authorization in the second half of 2021, was shipped from the production site of Promomed Group – the Biokhimik plant. The first hospitals where this essential drug to combat the complications of a new coronavirus infection was shipped are the Clinical Emergency Hospital No. 1 in Voronezh and the Clinical Hospitals No. 1 and No. 12 in Volgograd.
Enoparin® is an effective anticoagulant recommended by the Ministry of Health of the Russian Federation to prevent thrombosis and thromboembolism, common complications of coronavirus infection. These consequences are no less serious than the infection itself.
The main active ingredient of the drug, sodium enoxaparin, is isolated from the raw materials, low molecular weight heparins, using modern biotechnological methods of purification and sterilization. The drug is used for the prevention and treatment of deep vein thrombosis, prevention of ischemic complications of unstable angina and myocardial infarction.
Enoparin deliveries are planned to all regions of the country.